Aniruddha

CTD Series – Module 2.7.2: Building a Label-Ready Dose Rationale from IND to NDA

CTD-series /

Dossier Deep Dive · Part 3 Executive Snapshot Why 2.7.2 matters: This is the concise, integrated clinical pharmacology narrative that underpins dose, regimen, and labeling—read alongside the Clinical Overview (2.5) and substantiated by Module 5. Start at IND: Draft a light “2.7.2” scaffold (exposure metrics, covariates, DDI/food-effect plan, modeling shells) and harden iteratively through EoP2. […]

CTD Series – Module 2.7.2: Building a Label-Ready Dose Rationale from IND to NDA Read More »

Module 2: Integrating Clinical & Nonclinical Summaries From IND Through NDA

CTD-series /

Dossier Deep Dive · Part 2 Executive Snapshot Module 2 is the first thing reviewers read and the last thing many sponsors draft. Flip that. Start a “Module 2-lite” at IND: a reusable skeleton for 2.2–2.7 that you harden over time [1][2][3]. Integrate, don’t duplicate: use cross-references to Modules 3–5; keep one coherent benefit–risk narrative.

Module 2: Integrating Clinical & Nonclinical Summaries From IND Through NDA Read More »

Rethinking “Me-Too” Drugs: Leveraging Validated Pathways for Faster and Smarter Drug Development

Drug Development Strategy /

The CLUE framework for “next-in-class” and “me better” drugs. Introduction The term “me-too” drug has historically been used pejoratively to describe follow-on compounds perceived as redundant or commercially motivated imitations of first-in-class agents. Yet this view overlooks a critical reality of modern drug development: once a pathway or target is clinically validated, subsequent entrants can

Rethinking “Me-Too” Drugs: Leveraging Validated Pathways for Faster and Smarter Drug Development Read More »

AI in Preclinical and Clinical Drug Development: Opportunities, Challenges, and Practical Applications

Uncategorized /

Introduction Bringing a new therapy from concept to market is a long, complex, and resource-intensive process. Timelines typically extend 8–12 years and costs can exceed $2 billion [1]. Despite this investment, only about 10% of drugs entering clinical trials ultimately receive approval [2]. These inefficiencies stem from high attrition rates, translation gaps between preclinical and

AI in Preclinical and Clinical Drug Development: Opportunities, Challenges, and Practical Applications Read More »

Evolution of Therapeutic Modalities: FDA Approvals and Innovation Landscape

modalities /

Over the past several decades, drug development has expanded from traditional small-molecule chemicals to a diverse array of therapeutic modalities. These include biologics such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), nucleic acid-based therapies (siRNA, antisense oligonucleotides, mRNA vaccines), gene and cell therapies (including gene editing), and radiopharmaceuticals. In this deep dive, we explore the

Evolution of Therapeutic Modalities: FDA Approvals and Innovation Landscape Read More »

PBPK and QSP: Two Powerful Tools for Drug Development — When and Why to Use Each

Modeling and Simulation /

In today’s complex drug development landscape, PBPK and QSP modeling are key tools that help bridge data, de-risk decisions, and support regulatory interactions. PBPK Modeling Physiologically Based Pharmacokinetic (PBPK) models describe drug disposition in the body based on organ-specific physiology and biochemistry. They are commonly used for: PBPK is especially useful in early development and

PBPK and QSP: Two Powerful Tools for Drug Development — When and Why to Use Each Read More »

Reimagining Oncology Development: Leveraging Healthy Volunteers to De-Risk and Accelerate Your Program

Uncategorized /

Introduction Oncology drug development has traditionally shunned healthy volunteer (HV) participation due to the high toxicity of classic chemotherapies [1]. Cytotoxic agents non-selectively kill rapidly dividing cells, causing severe side effects that would be unethical in individuals without cancer. However, the therapeutic landscape is changing. Over the past two decades, targeted therapies—drugs aimed at specific

Reimagining Oncology Development: Leveraging Healthy Volunteers to De-Risk and Accelerate Your Program Read More »

Physiologically-Based PK (PBPK) Modeling: Your Fast-Pass for DDI & Food-Effect Strategy

Uncategorized /

Even if you never build a PBPK model in-house, an early decision framework—knowing when PBPK can replace, complement, or simply de-risk clinical studies—cuts duplicated work and answers “what-if” regulatory questions before they become clock-stopping RFIs. Why deciding early—not necessarily modeling early—saves studies, budget, and review stress Small molecule therapies—and, occasionally, intravenous antibody–drug conjugates (ADCs) carrying

Physiologically-Based PK (PBPK) Modeling: Your Fast-Pass for DDI & Food-Effect Strategy Read More »

IND vs IMPD: Building One Data Package That Satisfies Both FDA & EU Regulators

Uncategorized /

Executive snapshot Filing separate first-in-human (FIH) dossiers for the United States and Europe can drag an early-stage program six-plus months behind plan. A harmonised approach—one Common Technical Document (CTD) “master” that slots into both the FDA Investigational New Drug (IND) sequence and the EU Clinical Trials Regulation (CTR) portal (CTIS)—cuts review-cycle queries by ~35 %,

IND vs IMPD: Building One Data Package That Satisfies Both FDA & EU Regulators Read More »